Skip to main content
    Paid monthly and annual subscribers can read every Medi-Chi book online — including clinical references and the TCM Textbook · downloads sold separatelySee the libraryClinical Education Tool — This platform provides educational resources for TCM practitioners and students. It does not issue medical certificates, prescriptions, or clinical diagnoses.
    haematology and oncology

    Hodgkin lymphoma (supportive care)

    Also known as: Hodgkin lymphoma, Hodgkin's lymphoma, Hodgkin disease

    Hodgkin lymphoma is a malignancy of the lymphatic system that necessitates formal diagnosis, staging, and management by a haematologist. In this context, supportive care focuses on managing fatigue, appetite loss, nausea, sleep issues, and emotional distress as adjuncts to primary oncology treatment. While a TCM assessment may categorise these presentations into traditional patterns, it is important to note that TCM cannot determine lymphoma activity or monitor treatment outcomes. If acupuncture is considered, it requires prior oncology clearance and a careful individual assessment of risks relating to infection, bleeding, and anatomical changes. Any herbal prescriptions must be reviewed by an oncology pharmacist before use. The evidence cited here regarding CLL/SLL does not provide data for Hodgkin lymphoma, nor does it establish the efficacy of acupuncture or Chinese herbs for this specific condition. Traditional pattern changes or symptom improvements do not indicate tumour control.

    Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.

    All clinical details on this page are for practitioner premium subscribers only.
    Checking your practitioner access
    Verifying your Medi-Chi access…

    Lifestyle & Diet

    • •Maintain a comprehensive record of all pharmaceuticals, supplements, and herbal products; ensure the haematology team reviews this list prior to any modifications.
    • •Establish a manageable sleep routine and engage in gentle physical activity tailored to current symptoms and oncology advice; avoid pushing through dizziness or marked breathlessness.
    • •Prioritise well-tolerated foods, safe food handling, and hydration within medical restrictions; request dietetic support if oral intake or weight declines.
    • •Strictly adhere to oncological protocols regarding neutropenic precautions, immunisation schedules, and environmental pathogen exposure; utilise available psychosocial support services.

    Cautions & Contraindications

    See sources
    • •Defer acupuncture during fever, suspected infection, clinically significant neutropenia, thrombocytopenia or active bleeding until the oncology team confirms suitability using current clinical status and blood counts. These general safety precautions are not established by the supplied CLL/SLL abstract.[]
    • •Do not needle through tumour or enlarged nodes, infected or broken skin, vascular-access devices, recent surgical sites or acutely damaged irradiated skin. Avoid lymphoedematous or otherwise compromised areas unless specifically cleared. These general needling precautions are not established by the supplied CLL/SLL abstract.[]
    • •Do not initiate herbal formulas during anticancer treatment without review of the complete ingredients and interactions by the oncology team or pharmacist. Pregnancy, anticoagulants, liver or kidney impairment and electrolyte disturbances require additional assessment. This precaution is not established by the supplied CLL/SLL abstract, which provides no herbal safety data.[]

    When to reassess or seek care again

    See sources

    Establish baseline fatigue, nausea, sleep and distress scores on 0–10 scales, together with oral intake, vomiting frequency and functional activity. Review after each session and formally within 1–2 weeks, aligned with treatment cycles. Check current oncology instructions and relevant blood counts before further needling when counts may fluctuate. Pause adjunctive care and refer for worsening symptoms, new systemic features or suspected toxicity; discontinue an ineffective approach after 2–4 weeks rather than escalating empirically. Lymphoma response remains assessed exclusively through the haematology team's clinical and investigation plan.

    Explore more diseases

    Sources & Further Reading

    Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.

    1. Journal of the National Comprehensive Cancer Network : JNCCN · 2015

    Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.